The Impact of U.S. Tariffs on the Pharmaceutical Industry and Medicine Access in Europe: Challenges, Opportunities, and Future Outlook

Dear Editor,

The most tangible effect of tariffs is the increase in cost for imported pharmaceutical supplies, including active ingredients, raw materials, and finished products coming from Europe, China, India, and Ireland. This tariff increase translates into higher drug prices in the U.S., estimated at several hundred dollars more per family annually. ¹ Such cost increases threaten patient access to care, especially for generic and biosimilar medicines essential in oncology and other critical areas. Supply chain disruptions may cause shortages and therapy delays, negatively impacting treatment quality and health outcomes. ²

Additionally, tariffs create significant uncertainty in financial markets, negatively affecting research and development (R&D) investments, especially by small and mid-sized companies and startups that drive pharmaceutical innovation. These firms are particularly vulnerable to market volatility and operational cost increases, which could reduce R&D activities and potential new therapies. ¹

For Europe, the impact unfolds through two main channels: retaliatory tariffs by the European Union on U.S. pharmaceutical exports could raise drug prices on both sides, thereby worsening access for European patients. ² Moreover, regulatory and commercial uncertainties negatively influence the financial status and investment climate of European pharmaceutical firms operating globally, applying downward pressure on stock prices and sector investments. ³

These tariff tensions, within closely intertwined global supply chains between Europe and the U.S., disrupt already fragile supply mechanisms for sterile generics, antibiotics, and infusion therapies, increasing the risk of further shortages. ¹ Clinical research may also slow down if standard comparator drugs for trials become less available. ²

From the U.S. perspective, the declared goals of tariffs are to reduce trade deficits and strengthen domestic pharmaceutical production to enhance national health security. ¹ The expectation is that incentivizing domestic manufacturing will reduce foreign dependence and increase self-sufficiency.

However, reality shows that production switching requires long timelines (5-10 years or more) and high investments due to the specialized and regulated nature of pharmaceutical manufacturing. ² Additionally, many European companies already operate production plants in the U.S., which may benefit from tariff exemptions, somewhat limiting the total negative effect. ³

Experts suggest that more effective alternatives include tax incentives, targeted subsidies, industrial policies fostering domestic manufacturing, increased transparency in pricing and supply chains, and enhanced international cooperation. Such strategies could support domestic production without causing major market distortions or increasing drug costs. ¹

In Europe, the situation is prompting measures to boost the production of critical drugs, particularly oncology medicines, to reduce dependence on external suppliers. This push could strengthen the European pharmaceutical sector’s resilience and security. ² Some European industry groups have also proposed harmonizing drug prices and reimbursement policies aligned with the global tariff-impacted environment. ¹

Looking ahead, the effect of tariffs presents a delicate balance between economic protectionism and global interdependence in pharmaceuticals. Risks of cost increases, supply shortages, and innovation slowdowns may outweigh the short- and medium-term gains in domestic production. ²

The European Union is already taking steps to increase production of essential medicines and protect access, including utilizing defense funds and coherent industrial policies in light of current geopolitical tensions. ²

Furthermore, the concept of tariffs as a form of economic warfare highlights their broader health consequences. Additional costs and disruptions in healthcare systems in both the U.S. and Europe may worsen public health indicators and access to care, underscoring the need for effective mitigation strategies. ¹

Within this challenging landscape, hospital pharmacists emerge as critical actors in managing the risks associated with tariff-induced supply disruptions. Their expertise in drug supply chain management positions them at the frontline of mitigating shortages through strategic inventory control, alternative sourcing, and therapeutic substitution where appropriate. Furthermore, hospital pharmacists play a vital role in negotiating procurement contracts under volatile market conditions and advocating for patient-centered policies to maintain access to essential medicines despite cost pressures. ²

In addition, hospital pharmacists contribute to safeguarding the quality of care amid uncertainties by optimizing drug use protocols, supporting clinical trials, and ensuring continuity of therapy in oncology and other specialized fields where generic and biosimilar medicines—most affected by tariffs—are critical. By providing real-time information and guidance to healthcare teams, hospital pharmacists help balance cost-efficiency with patient safety, which is paramount in times of economic and supply fluctuations. ¹

The evolving geopolitical and economic context underscores the necessity of empowering hospital pharmacists with enhanced resources, timely data, and a central role in policy discussions. Their involvement is indispensable to crafting resilient pharmaceutical supply strategies that can withstand external shocks such as tariffs, thereby protecting patient outcomes and public health on a transnational scale. ⁴

In conclusion, while U.S. tariffs might theoretically encourage domestic pharma manufacturing, practical limitations reduce their short-term effectiveness. Meanwhile, Europe is urged to strengthen its pharmaceutical capacity and manage the commercial and health consequences of transatlantic trade tensions, leveraging international cooperation and strategic industrial policies.

Eleonora Castellana and Maria Rachele Chiappetta
Hospital Pharmacy, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy